炎症性肠病(inflammatory bowel disease,IBD)主要包括溃疡性结肠炎(ulcerative colitis,UC)和克罗恩病(Crohn's disease,CD).随着对疾病认识的不断加深、新药研发及新的循证医学证据的出现,对于IBD的治疗理念也发生着日新月异的变化.2022年初欧洲克罗恩和结肠炎组织(European Crohn's and Colitis Organi-sation,ECCO)正式发布了 UC治疗指南,分为药物治疗篇和手术治疗篇.本文对照2017版ECCO共识,针对ECCO最新UC治疗指南,结合最新循证医学证据进行解读,以帮助临床医生更好地了解国内外UC治疗的新策略,提高UC的诊疗水平.
Introduction of the latest ECCO Guidelines on therapeutics in ulcerative colitis
Inflammatory bowel disease(IBD)mainly includes ulcerative colitis(UC)and Crohn's disease(CD).With the continuous deepening of understanding of IBD,the development of new drugs,and the emergence of new evidence-based medicine,the treatment concepts for IBD are also undergoing rapid changes.In early 2022,the European Crohn's and Colitis Organisation(ECCO)officially published guidelines for the treatment of UC,which including medical treatment and surgical treatment sections.This article compares the 2017 version of the ECCO consensus and interprets the latest UC treatment guidelines,based on the latest evidence-based medicine evidence,in order to help clinicians better understanding the new strategies for UC treatment and improve the lev-el of UC diagnosis and treatment.
European Crohn's and Colitis Organisationulcerative colitisguidelines on therapeutics
NETL
NSTL
万方数据
